Our data suggest a scenario where proliferative responses to IL-7 would be favored in a narrow window of time upon thymic egress, which has important implications to the therapeutic use of IL-7 in clinical settings known to be associated with thymic injury, namely, HIV/AIDS (67, 68) and chemotherapy (69, 70). The gene discussed is IL7; the disease is AIDS.